These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3054627)

  • 1. [Immunotherapy of parenchymal tumors. Recent progress and theoretical considerations].
    Marincola F; Smolik L; Annoni F; Holter WD
    Minerva Chir; 1988 Jul; 43(13-14):1111-31. PubMed ID: 3054627
    [No Abstract]   [Full Text] [Related]  

  • 2. Natural killer cells and tumor immunity: 1987.
    Hiserodt JC; Herberman RB
    Year Immunol; 1989; 4():201-7. PubMed ID: 2648702
    [No Abstract]   [Full Text] [Related]  

  • 3. Pre-clinical models for immunotherapy of melanoma.
    Reisfeld RA
    Prog Clin Biol Res; 1989; 288():183-93. PubMed ID: 2654950
    [No Abstract]   [Full Text] [Related]  

  • 4. [Induction of tumoricidal effectors from the tumor-bearer's splenocytes and the prospects of their utilization for adoptive immunotherapy].
    Takagi H; Okuno K; Nakamura T; Kokudo S; Iwasa Z; Yasutomi M
    Nihon Gan Chiryo Gakkai Shi; 1986 May; 21(4):721-7. PubMed ID: 3489799
    [No Abstract]   [Full Text] [Related]  

  • 5. [A new approach to immunotherapy of cancer based on autologous T-lymphocytes].
    Dosne Pasqualini C; Laguens RP
    Medicina (B Aires); 1987; 47(3):307-12. PubMed ID: 3326997
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunotherapy of malignant diseases].
    Dorval T; Michon J; Tartour E; Fridman WH
    Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
    Reisfeld RA; Gillies SD
    J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of interleukin-2 and lymphokine-activated killer cells on cell cultures and on transplanted tumors (nude mouse) of human pancreatic carcinomas].
    Kühl JS; Klapdor R; Bahlo M; Arps H; Dietel M; Mohr M
    Beitr Infusionther Klin Ernahr; 1987; 18():261-5. PubMed ID: 3501948
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The interleukin-2-LAK system in cancerology].
    Fridman WH
    Pathol Biol (Paris); 1989 Feb; 37(2):94-5. PubMed ID: 2652081
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism].
    Kosugi A; Fujiwara H; Hamaoka T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1527-35. PubMed ID: 6236750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological response modifiers: the new immunotherapy.
    Foon KA
    Cancer Res; 1989 Apr; 49(7):1621-39. PubMed ID: 2466558
    [No Abstract]   [Full Text] [Related]  

  • 14. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Hooijberg E; Sein JJ; van den Berk PC; Hart AA; van der Valk MA; Kast WM; Melief CJ; Hekman A
    Cancer Res; 1995 Jun; 55(12):2627-34. PubMed ID: 7540106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of monoclonal antibodies in the immunotherapy of neoplasms].
    Robak T
    Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121
    [No Abstract]   [Full Text] [Related]  

  • 16. [Using LAK cells in the adoptive immunotherapy in cancers].
    Urushizaki I
    Rinsho Ketsueki; 1987 Oct; 28(10):1897-8. PubMed ID: 3502569
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cocktails of human anti-cancer antibodies show a synergistic effect in nude mouse tumor xenografts.
    Glassy MC; McKnight ME; Kotlan B; Glassy EF; Koda K
    Hum Antibodies; 2007; 16(3-4):87-98. PubMed ID: 18334744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological immunomodulators in the treatment of cancer].
    Bello C; Richard C; Hermosa V; Iriondo A; Muruzábal MJ; Pérez Encinas M; Zubizarreta A
    Sangre (Barc); 1988 Apr; 33(2):132-43. PubMed ID: 2456623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.